Lead Product(s): Epinephrine Bitartrate
Therapeutic Area: Immunology Product Name: Jext
Highest Development Status: Approved Product Type: Small molecule
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 30, 2021
Jext® is expected to be the first AAI to market in China. Prior to registration in mainland China, Grandpharma plans to start selling Jext® in southern China under a special licence linked to the existing registration of Jext® in Hong Kong.